We support the adoption of stronger quality measures for HIV and viral hepatitis, including screening and treatment for hepatitis B and C, as well as a more accurate ADAP 340B calculation for the Medicare drug inflation rebate. Federal & state quality measures help ensure that health systems prioritize these key interventions.
Comments to CMS on their proposed rule to codify the Medicare price negotiation program
This rulemaking is the first opportunity to codify the Negotiation Program in binding regulatory text rather than annual sub-regulatory guidance, and codification is the appropriate moment to close these gaps. Patients were promised that this program would deliver meaningful affordability and access improvements, and CMS should use this rulemaking to make good on that promise through enforceable, not merely discretionary, standards. Our comments address patient engagement in the negotiation process, transparency in how patient input is used, formulary access and utilization management protections for selected drugs, and additional concerns about the negotiation methodology itself.
Medicare Drug Price Negotiation Town Hall Testimony on Biktarvy
The drug development pipeline is full of promise. Long-acting formulations make adherence easier; new drug classes may produce options for those with a high resistance burden or those who still struggle with side effects. Continued drug development will yield new options for an aging population with HIV and multiple comorbidities, who face high levels of stigma and discrimination and structural and social barriers to uninterrupted care. As Medicare’s HIV population is expected to double by 2035, we need continued innovation alongside continued access to current and new treatments.
Comments to CMS Administrator Oz opposing the Guarding U.S. Medicare Against Rising Drug Costs (GUARD) model
The HIV+Hepatitis Policy Institute strongly opposes the GUARD Model because it prioritizes projected federal savings over the health and financial stability of Medicare beneficiaries. By moving forward with a framework that acknowledges multibillion-dollar cost increases for patients and relies on a retrospective monitoring system, CMS leaves those who depend on continuous, life-sustaining treatment without meaningful protection from harm. We urge CMS to withdraw this proposal and instead pursue alternative reforms that offer immediate, point-of-sale affordability without jeopardizing treatment access, destabilizing essential safety nets, or undermining the research and development necessary to reach future therapeutic advances and cures.
Oppose Delaware Senate joint resolution 7 imposing price controls in state employee health plans
While we support efforts to make prescription drugs more affordable, we respectfully urge you to oppose Delaware Senate Joint Resolution 7 because it would impose harmful and untested price controls in state employee health plans without guaranteeing savings for patients.